Wilprafen
Wilprafen: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Drug interactions
- 11. Analogs
- 12. Terms and conditions of storage
- 13. Terms of dispensing from pharmacies
- 14. Reviews
- 15. Price in pharmacies
Latin name: Wilprafen
ATX code: J01FA07
Active ingredient: josamycin (josamycin)
Manufacturer: Yamanouchi Pharma for Heinrich Mack Nachf. (Germany)
Description and photo update: 2019-16-08
Prices in pharmacies: from 23 rubles.
Buy
Wilprafen is an antibiotic of the macrolide group with bactericidal action.
Release form and composition
Vilprafen is produced in the form of film-coated tablets - biconvex, oblong, almost white or white, with risks on both sides (10 pcs. In blisters, 1 blister in a cardboard box).
The composition of 1 tablet contains the active ingredient josamycin, in an amount of 500 mg.
Auxiliary components in 1 tablet: polysorbate 80 - 5 mg; magnesium stearate - 5 mg; microcrystalline cellulose - 101 mg; colloidal silicon dioxide - 14 mg; carmellose sodium - 10 mg.
Shell composition: polyethylene glycol 6000 - 0.3846 mg; methylcellulose - 0.12825 mg; titanium dioxide - 0.641 mg; talc - 2.0513 mg; copolymer of methacrylic acid and its esters - 1.15385 mg; aluminum hydroxide - 0.641 mg.
Pharmacological properties
Pharmacodynamics
The mechanism of action of josamycin is to inhibit the production of protein in the microbial cell, which is explained by reversible binding to the 50S-subunit of the ribosome. Usually in therapeutic concentrations, the active component of the drug is characterized by a bacteriostatic effect, which leads to inhibition of the growth and reproduction of bacteria. If high concentrations of josamycin are created in the inflammatory focus, manifestations of a bactericidal effect are observed.
Josamycin is active against the following microorganisms:
- gram-positive bacteria: Staphylococcus spp. (including methicillin-sensitive strains of Staphylococcus aureus), Peptostreptococcus spp., Streptococcus spp. (including Streptococcus pneumoniae and Streptococcus pyogenes), Peptococcus spp., Corynebacterium diphtheriae, Clostridium spp., Listeria monocytogenes, Bacillus anthracis, Propionibacterium acnes;
- gram-negative bacteria: Campylobacter jejuni, Neisseria gonorrhoeae, Neisseria meningitides, Helicobacter pylori, Moraxella catarrhalis, Haemophilus influenzae, Haemophilus ducreyi, Legionella spp., Brucella spp., Bordetella spp.;
- others: Borrelia burgdorferi, Bacteroides fragilis (the sensitivity of josamycin may be variable), Treponema pallidum, Chlamydia spp. (including Chlamydia trachomatis), Ureaplasma spp., Mycoplasma spp. (including Mycoplasma genitalium, Mycoplasma hominis, Mycoplasma pneumoniae), Chlamydophila spp. (including Chlamydophila pneumoniae).
As a rule, enterobacteria are resistant to josamycin, therefore its use insignificantly affects the microflora of the gastrointestinal tract (GIT). The active ingredient also demonstrates activity in diagnosed resistance to erythromycin and other 14- and 15-membered macrolides. Cases of resistance to josamycin are reported less frequently than to 14- and 15-membered macrolides.
Pharmacokinetics
After oral administration, josamycin is absorbed from the gastrointestinal tract at a high rate; food intake does not change its bioavailability. The maximum concentration of the substance in plasma is reached 1 hour after ingestion. When taking Vilprafen at a dose of 1 g, the maximum level of its active substance in the blood plasma is 2–3 μg / ml. The degree of binding of josamycin to plasma proteins is approximately 15%. The compound is well distributed in tissues and organs (excluding the brain), and its concentrations often exceed plasma levels and retain therapeutic efficacy for a long time. Especially high concentrations of josamycin are found in lacrimal fluid, saliva, sweat, tonsils and lungs. Its content in sputum exceeds the content in plasma by 8-9 times.
Josamycin crosses the placental barrier and passes into breast milk. The compound is metabolized in the liver, forming metabolites with less pharmacological activity. Josamycin is excreted mainly in the bile. Its half-life is 1–2 hours, but this figure can be lengthened in patients with liver dysfunctions. The degree of excretion of the drug in the urine does not exceed 10%.
Indications for use
Vilprafen tablets 500 mg are prescribed for the treatment of infectious and inflammatory diseases caused by microorganisms sensitive to the action of the active substance (josamycin):
- Lower respiratory tract infections - acute bronchitis, whooping cough, bronchopneumonia, psittacosis, pneumonia, including the atypical form;
- Infections of ENT organs and upper respiratory tract - sinusitis, tonsillitis, paratonsillitis, pharyngitis, otitis media, laryngitis;
- Oral infections - periodontal disease and gingivitis;
- Scarlet fever (with hypersensitivity to penicillin);
- Diphtheria (in addition to diphtheria antitoxin therapy);
- Genital and urinary tract infections - prostatitis, urethritis, gonorrhea; with hypersensitivity to penicillin - lymphogranuloma venereum, syphilis;
- Mycoplasma (including ureaplasma), chlamydial and mixed infections of the genital organs and urinary tract;
- Infections of soft tissues and skin - lymphadenitis, lymphangitis, boils, pyoderma, acne, anthrax, erysipelas (with hypersensitivity to penicillin).
Contraindications
- Severe functional disorders of the liver;
- Hypersensitivity to the components of the drug and other antibiotics of the macrolide group.
Breastfeeding and pregnant women should only take Wilprafen in cases where the expected health benefits to the mother outweigh the possible risk to the fetus or baby.
Instructions for the use of Vilprafen: method and dosage
Wilprafen is taken orally between meals. The tablet should be swallowed whole and washed down with a little water.
For adolescents over the age of 14 and adults, the recommended daily dose is 1-2 g of Wilprafen, which must be divided into 2-3 doses. The initial recommended dose is 1 g.
With globular and acne vulgaris, 0.5 g of josamycin is prescribed 2 times a day during the first 2-4 weeks, then, within 2 months, the frequency of use is reduced to 0.5 g of josamycin once a day (as maintenance therapy).
The duration of treatment is usually determined by the doctor. According to the recommendations of the World Health Organization on the use of antibiotic drugs, the duration of therapy for streptococcal infections should be at least 10 days.
If a single dose of Vilprafen is missed, you need to take the dose immediately. In cases where the time has come for the next dose of the drug, the dose should not be increased.
A break in therapy or premature discontinuation of the drug reduces the likelihood of treatment success.
Side effects
While taking Vilprafen, disorders may develop from various body systems:
- Gastrointestinal tract: rarely - heartburn, nausea, loss of appetite, diarrhea and vomiting. With severe persistent diarrhea, one must bear in mind the possibility of developing pseudomembranous colitis (which is life threatening) due to the action of an antibiotic;
- Hearing aid: in rare cases - dose-dependent transient hearing impairment;
- Biliary tract and liver: in some cases - a transient increase in the activity of liver enzymes in the blood plasma, sometimes accompanied by jaundice and impaired outflow of bile;
- Hypersensitivity reactions: in some cases - allergic skin reactions (for example, urticaria).
Overdose
To date, there is practically no information about the specific symptoms of Wilprafen overdose. In this case, it is worthwhile to assume an increase in the severity of side reactions of the drug, mainly from the gastrointestinal tract.
special instructions
With the development of pseudomembranous colitis, Wilprafen should be canceled and appropriate treatment prescribed. Taking drugs that reduce intestinal motility is contraindicated.
Patients with renal insufficiency need to adjust the dosage regimen in accordance with the values of creatinine clearance (CC).
According to the instructions, Vilprafen is not prescribed for premature babies. When used in newborns, liver function should be monitored.
It is necessary to take into account the possibility of cross-resistance to various antibiotic drugs of the macrolide group.
Influence on the ability to drive vehicles and complex mechanisms
It was found that the use of Wilprafen does not affect the ability to drive vehicles and perform potentially dangerous types of work associated with increased concentration and speed of reactions.
Application during pregnancy and lactation
During pregnancy and during breastfeeding, the drug can be prescribed if the benefits of its use to the mother outweigh the potential risk to the fetus or child. The doctor should evaluate the possible consequences of taking this drug and only then prescribe a course of treatment.
The WHO European Office recommends Wilprafen as a drug for the treatment of chlamydial infection in pregnant women.
During therapy with josamycin, combined with the use of hormonal methods of contraception, additional protection in the form of non-hormonal contraceptives should be used.
Drug interactions
The simultaneous use of Vilprafen with cephalosporins and penicillins should be avoided.
When used together with lincomycin, the effectiveness of both drugs may decrease.
Wilprafen slows down the elimination of theophylline to a lesser extent than other antibiotic drugs of the macrolide group.
With simultaneous use with cyclosporine, an increase in its concentration in blood plasma up to nephrotoxic is possible.
There are reports of an increase in vasoconstrictor action with the combined use of ergot alkaloids, antibiotics and drugs of the macrolide group.
Vilprafen slows down the elimination of astemizole or terfenadine, which increases the risk of developing life-threatening arrhythmias.
With simultaneous use with digoxin, an increase in the level of the latter in blood plasma is possible.
With the simultaneous use of the drug with hormonal contraceptives, it is additionally necessary to use non-hormonal contraceptives.
Analogs
Vilprafen's analogue is Vilprafen Solutab.
Terms and conditions of storage
Store in a dark place, out of reach of children, at temperatures up to 25 ° C.
Shelf life is 4 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews about Wilprafen
According to reviews, Vilprafen is a fairly effective drug, but the risk of developing adverse reactions during treatment is quite high. Patients who have been diagnosed with chlamydia and ureaplasmosis report that within a few days after starting to use the drug, the symptoms of the diseases disappear without a trace. There are reports of such side effects of Wilprafen as gastrointestinal disturbances and allergic rashes, which are relatively common.
Many patients recommend the drug as an effective remedy for sinusitis and other infectious diseases. Often it is prescribed to children whose treatment gives good results, but sometimes parents complain of manifestations of dysbiosis.
Price for Wilprafen in pharmacies
On average, the price for Vilprafen 500 mg in pharmacies is 515-596 rubles (10 tablets per pack).
Wilprafen: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Vilprafen granules for suspension for internal approx. 125mg / 5ml fl. 15g RUB 23 Buy |
|
Wilprafen 125 mg / 5 ml granules for preparation of oral suspension 15 g 1 pc. RUB 23 Buy |
|
Vilprafen 500 mg film-coated tablets 10 pcs. 453 r Buy |
|
Vilprafen 500 mg / 5 ml granules for preparation of oral suspension 20 g 1 pc. 458 r Buy |
|
Vilprafen 250 mg / 5 ml granules for preparation of oral suspension 15 g 1 pc. 489 r Buy |
|
Vilprafen granules for suspension for internal approx. 500mg / 5ml fl. 20g 497 r Buy |
|
Vilprafen Solutab 1000 mg dispersible tablets 10 pcs. RUB 550 Buy |
|
Reviews Wilprafen solutab RUB 550 Buy |
|
Vilprafen tablets p.o. 500mg 10 pcs. 603 RUB Buy |
|
Vilprafen Solutab tablets dispersion 1000mg 10 pcs. 707 r Buy |
|
Vilprafen 500 mg film-coated tablets 30 pcs. 1023 RUB Buy |
|
Wilprafen tab. p / o film. 500 mg 30 pcs. 1325 RUB Buy |
| See all offers from pharmacies |
Maria Kulkes Medical journalist About the author
Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
